(Total Views: 571)
Posted On: 10/22/2021 1:20:25 PM
Post# of 145247
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Hi all. After a long break from this board, I wanted to pose a two part question regarding our NASH trial. I see that Inventiva Pharm has recently begun a lengthy phase 3 trial for NASH and I believe that they received BTD for NASH in 2019. Question 1 - do we consider their drug Lanifibranor to be a true competitor to Leronlimab for NASH; Question 2 - why doesn't Inventiva's market cap reflect anything near the $8 billion market cap that I thought is supposed to come along with a BTD? For the record, I am still long and strong Cytodyn, and I have never sold a share of my investment! Thanks.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)